Treatment of Pubertal Gynecomastia with the Specific Aromatase Inhibitor Anastrozole
Authors:
- Inka BausIBInka Baus
- Stephanie WiestSWStephanie Wiest
- Nils KroneNKNils Krone
- Wolfgang G. SippellWSWolfgang G. Sippell
- Carl-Joachim PartschCPCarl-Joachim Partsch
- 1 September 2004
- journal article
- clinical trial
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 62 (3) , 113-118
Abstract
Gynecomastia can be detected in up to 70% of boys during puberty and in about one third of adult males. An imbalance of estrogen to androgen tissue levels is believed to be the major reason for the development of gynecomastia; as a result most medical treatments so far have tried to lower the estrogen level. Five boys with pubertal gynecomastia and breast tenderness were treated for 6 months with the selective aromatase inhibitor anastrozole. Initial plasma levels of estradiol (E2), testosterone (T), androstenedione, dehydroepiandrosterone sulfate (DHEA-S) and gonadotropins were normal. DHEA-S showed a significant rise during treatment. T and androstenedione showed no significant change during treatment. E2 decreased with therapy, although to no statistically significant extent. The E2/T ratio decreased significantly during the treatment. Breast size decreased in 4 out of 5 patients, and in 1 of these 4 boys glandular breast tissue disappeared completely. The longer the duration of gynecomastia before anastrozole administration, the smaller was the reduction of breast size. Breast tenderness was resolved in all boys within 4 weeks. No adverse effects were recorded. Since the aim of medical treatment is the total disappearance of breast tissue, anastrozole, as previous aromatase inhibitors, is of limited effect. However, anastrozole seems to be of benefit for the treatment of tenderness in gynecomastia and for patients in whom surgery is particularly risky. However, as spontaneous disappearance of pubertal gynecomastia is common, further double-blinded, placebo-controlled trials are necessary before a definite conclusion can be drawn about the effectiveness and the side effects of this therapy.Keywords
This publication has 20 references indexed in Scilit:
- Pubertal GynecomastiaJournal of Pediatric Endocrinology and Metabolism, 2002
- A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trialThe Lancet, 2001
- Clinical, Endocrine, and Molecular Genetic Findings in Patients with 17β-Hydroxysteroid Dehydrogenase DeficiencyHormone Research in Paediatrics, 2000
- Aromatase and gynecomastia.Endocrine-Related Cancer, 1999
- Acute Effects of Estradiol Infusion and Naloxone on Luteinizing Hormone Secretion in Pubertal BoysThe Journal of Clinical Endocrinology & Metabolism, 1997
- New aromatase inhibitors: More selectivity, less toxicity, unfortunately, the same activityEuropean Journal of Cancer, 1996
- ARIMIDEX™: A new oral, once-a-day aromatase inhibitorThe Journal of Steroid Biochemistry and Molecular Biology, 1995
- Behandlung der ausgeprägten Pubertätsgynäkomastie mit TamoxifenKlinische Padiatrie, 1987
- Role of endogenous opiates in the expression of negative feedback actions of androgen and estrogen on pulsatile properties of luteinizing hormone secretion in man.Journal of Clinical Investigation, 1984
- RADIOGRAPHIC ATLAS OF SKELETAL DEVELOPMENT OF THE HAND AND WRISTThe American Journal of the Medical Sciences, 1959